- Home
- GAM vs PSNL Comparison
GAM vs PSNL Comparison
Compare GAM & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAM | PSNL |
|---|---|---|
| Founded | 1927 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GAM | PSNL |
|---|---|---|
| Price | $67.13 | $14.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 18.4K | ★ 4.7M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $5.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $56.24 | $4.43 |
| 52 Week High | $67.07 | $16.39 |
Technical Indicators
Market Signals| Indicator | GAM | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 70.65 | 51.90 |
| Support Level | $62.30 | $6.68 |
| Resistance Level | N/A | $16.39 |
| Average True Range (ATR) | 0.81 | 0.75 |
| MACD | 0.23 | -0.08 |
| Stochastic Oscillator | 89.08 | 46.75 |
Price Performance
Historical ComparisonAbout GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.